Needham Reiterates Buy on ResMed, Maintains $236 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on ResMed (NYSE:RMD) and maintained a price target of $236.
June 24, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on ResMed and maintained a price target of $236.
The reiteration of a Buy rating and the maintenance of a $236 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100